Registered report: Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases

IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition

(2014) A. Kernytsky et al.   BLOOD

D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice

(2014) E. A. Akbay et al.   GENES & DEVELOPMENT

An open investigation of the reproducibility of cancer biology research

(2014) Timothy M Errington et al.   eLife

Isocitrate dehydrogenase mutations in leukemia

(2013) Anna Sophia McKenney et al.   JOURNAL OF CLINICAL INVESTIGATION

MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis

(2013) Atsushi Terunuma et al.   JOURNAL OF CLINICAL INVESTIGATION

A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation

(2012) C. G. Duncan et al.   GENOME RESEARCH

IDH mutation impairs histone demethylation and results in a block to cell differentiation

(2012) Chao Lu et al.   NATURE

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

(2012) Sevin Turcan et al.   NATURE

IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics

(2012) Masato Sasaki et al.   NATURE

Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases

(2011) Wei Xu et al.   CANCER CELL

The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate

(2010) Patrick S. Ward et al.   CANCER CELL

Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation

(2010) Maria E. Figueroa et al.   CANCER CELL

Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification

(2010) Shinsuke Ito et al.   NATURE